Detection of Acute Graft Rejection in Heart Transplant Patients by Estimation of T2 (DRAGET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02261870|
Recruitment Status : Recruiting
First Posted : October 10, 2014
Last Update Posted : July 31, 2017
The investigators propose a simple and non-invasive method to monitor heart transplant patients with MRI. Its diagnostic and prognostic values have already been assessed in two monocentric studies. Other monocentric studies based on related methods have confirmed the investigators findings. These studies are insufficient to allow a large diffusion of the technique. Only a large multi-centric study will change medical practices. In addition, this project will spread the new method at a national level and will allow an assessment of its practical usefulness in centres not familiar with MRI T2 quantification.
Furthermore, MRI seems to detect rejections at earlier stage than biopsy. A confirmation of this observation could lead to a modification of diagnostic criteria of cardiac graft rejection. The ultimate aim of the DRAGET project is to replace a strategy based solely on biopsy with one based on a first-line MRI (with biopsy only when needed) for a more efficient and earlier detection of rejection. This would constitute a major advance in patients security and comfort as well as an economic improvement.
|Condition or disease||Intervention/treatment||Phase|
|Acute Graft Rejection Heart Transplantation||Device: MRI T2 quantification||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||190 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||"Detection of Acute Rejection in Heart Transplant Patients by Mean of T2 Quantification With MRI" Open Transversal Clinical Trial With Repeated Measures|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||July 2018|
MRI T2 quantification : heart transplant patients will have 4-6 MRI exams for T2 quantification during their first year after transplantation.
Device: MRI T2 quantification
MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
- Sensitivity and specificity of myocardial T2 assessed with MRI for the diagnosis of histological heart graft rejection (with 95% confidence interval). [ Time Frame: 3 years after first inclusion ]endpoint = sensitivity and specificity acute rejection means presence of damaged myocytes in endomyocardial biopsy (former grade 2, grade 2R and grade 3R)
- Incidence of histological or clinical rejection within months of a couple MRI/biopsy with normal biopsy (grade<2R). [ Time Frame: 3 years after first inclusion ]endpoint = number of rejections For this purpose, rejection will be defined as: a) acute rejection documented by presence of damaged myocytes in endomyocardial biopsy (former grade 2, grade 2R and grade 3R), or b) marked decrease in left ventricle ejection fraction (>10%), reversible after subsequent increase in immunosuppressive treatment.
- Complications with MRI and with biopsies. [ Time Frame: 3 years after first inclusion ]endpoint = Number of adverse events due to both exams
- Magnitude of better tolerability of MRI over biopsies for the patient. [ Time Frame: 3 years after first inclusion ]endpoint = Physical and psychological distress assessed by questionnaire using Likert scales. This questionnaire will be completed by the patients.
- Inter-observer reproducibility of T2 quantification with MRI and of pathological grading of the biopsies. [ Time Frame: 3 years after first inclusion ]endpoint = 95% interobserver limit of agreement for T2 quantification and Cohen's Kappa coefficient for histological grading.
- Level of confidence, at the end of the study, of the expert-physicians of each centre concerning the use of T2 quantification as an alternative to routine biopsies. [ Time Frame: 3 years after first inclusion ]endpoint = Confidence assessed by questionnaire using Likert scales. This questionnaire will be completed by study investigators at the end of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02261870
|Contact: Laurent Bonnemains, MD, PhDemail@example.com|
|Contact: Aboubaker Cherififirstname.lastname@example.org|
|Hospices Civils de Lyon||Not yet recruiting|
|Bron, France, 69677|
|Contact: Laurent SEBBAG, Dr.|
|La Tronche, France, 38700|
|Contact: Gilles BARONE-ROCHETTE, Dr.|
|CHRU Nancy Brabois||Recruiting|
|Contact: Pierre Yves Marie, MD, PHD|
|CHU de Nantes||Recruiting|
|Nantes, France, 44093|
|Contact: Magali MICHEL, Dr.|
|Hôpital Européen Georges Pompidou||Recruiting|
|Paris, France, 75015|
|Contact: Elie MOUSSEAUX, Pr.|
|Groupe Hospitalier Pitié-Salpêtrière||Recruiting|
|Paris, France, 75651|
|Contact: Philippe CLUZEL, Dr.|
|Pessac, France, 33604|
|Contact: François LAURENT, Pr.|
|CHU de Rennes||Recruiting|
|Rennes, France, 35033|
|Contact: Céline CHABANNE, Dr.|
|Hopitaux Universitaires de Strasbourg||Active, not recruiting|
|CHU de Tours||Recruiting|
|Tours, France, 37044|
|Contact: Emmanuelle VERMES, Dr.|
|Principal Investigator:||Laurent Bonnemains, MD, PhD||INSERM, IADI U47, Nancy, France|